Raffles Medical Set to Gain as Singapore's Medical Tourism Recovers -- Market Talk
Raffles Medical Set to Gain as Singapore's Medical Tourism Recovers -- Market Talk
0633 GMT - Raffles Medical Group stands to benefit from medical tourism gradually returning to Singapore as the country reopens its borders, DBS Research says. Covid-19-related services like vaccinations are expected to taper, but the company remains a key provider of polymerase-chain-reaction tests at Singapore's Changi Airport and will likely benefit from pent-up travel demand, DBS adds. It expects Raffles Medical to post record earnings in 2022-23 and keeps a buy rating on the stock while raising the target price to S$1.81 from S$1.48. Shares rise 2.0% to S$1.53. (yongchang.chin@wsj.com)
0633GMT-星展研究(DBS Research)表示，隨着新加坡重新開放邊境，萊佛士醫療集團(Raffles Medical Group)將受益於逐漸返回新加坡的醫療旅遊。星展銀行補充説，疫苗接種等新冠肺炎相關服務預計將逐步減少，但該公司仍是新加坡樟宜機場聚合酶鏈式反應檢測的主要供應商，可能會受益於被壓抑的旅遊需求。該公司預計萊佛士醫療公司(Raffles Medical)將在2022-23年公佈創紀錄的收益，並維持對該股的買入評級，同時將目標價從1.48新元上調至1.81新元。股價上漲2.0%，至1.53新元。(yongchang.chin@wsj.com)
譯文內容由第三人軟體翻譯。
